Logo image of SIBN

SI-BONE INC (SIBN) Stock Fundamental Analysis

USA - NASDAQ:SIBN - US8257041090 - Common Stock

14.05 USD
-0.09 (-0.64%)
Last: 9/26/2025, 8:00:02 PM
14.05 USD
0 (0%)
After Hours: 9/26/2025, 8:00:02 PM
Fundamental Rating

3

Overall SIBN gets a fundamental rating of 3 out of 10. We evaluated SIBN against 191 industry peers in the Health Care Equipment & Supplies industry. SIBN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SIBN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SIBN has reported negative net income.
SIBN had a negative operating cash flow in the past year.
SIBN had negative earnings in each of the past 5 years.
In the past 5 years SIBN always reported negative operating cash flow.
SIBN Yearly Net Income VS EBIT VS OCF VS FCFSIBN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -10.29%, SIBN is doing good in the industry, outperforming 61.78% of the companies in the same industry.
The Return On Equity of SIBN (-13.95%) is better than 63.87% of its industry peers.
Industry RankSector Rank
ROA -10.29%
ROE -13.95%
ROIC N/A
ROA(3y)-23.71%
ROA(5y)-24.08%
ROE(3y)-35.49%
ROE(5y)-34.87%
ROIC(3y)N/A
ROIC(5y)N/A
SIBN Yearly ROA, ROE, ROICSIBN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

1.3 Margins

SIBN's Gross Margin of 79.45% is amongst the best of the industry. SIBN outperforms 92.15% of its industry peers.
In the last couple of years the Gross Margin of SIBN has declined.
SIBN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.65%
GM growth 5Y-2.54%
SIBN Yearly Profit, Operating, Gross MarginsSIBN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SIBN has more shares outstanding
The number of shares outstanding for SIBN has been increased compared to 5 years ago.
SIBN has a better debt/assets ratio than last year.
SIBN Yearly Shares OutstandingSIBN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SIBN Yearly Total Debt VS Total AssetsSIBN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 4.67 indicates that SIBN is not in any danger for bankruptcy at the moment.
SIBN has a better Altman-Z score (4.67) than 79.58% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SIBN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.21, SIBN is in line with its industry, outperforming 56.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 4.67
ROIC/WACCN/A
WACC8.76%
SIBN Yearly LT Debt VS Equity VS FCFSIBN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 8.38 indicates that SIBN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.38, SIBN belongs to the top of the industry, outperforming 89.01% of the companies in the same industry.
A Quick Ratio of 7.00 indicates that SIBN has no problem at all paying its short term obligations.
The Quick ratio of SIBN (7.00) is better than 88.48% of its industry peers.
Industry RankSector Rank
Current Ratio 8.38
Quick Ratio 7
SIBN Yearly Current Assets VS Current LiabilitesSIBN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.55% over the past year.
Looking at the last year, SIBN shows a very strong growth in Revenue. The Revenue has grown by 22.93%.
The Revenue has been growing by 19.96% on average over the past years. This is quite good.
EPS 1Y (TTM)44.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)22.93%
Revenue growth 3Y22.84%
Revenue growth 5Y19.96%
Sales Q2Q%21.67%

3.2 Future

The Earnings Per Share is expected to grow by 14.39% on average over the next years. This is quite good.
SIBN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.49% yearly.
EPS Next Y20%
EPS Next 2Y16.01%
EPS Next 3Y14.39%
EPS Next 5YN/A
Revenue Next Year18.3%
Revenue Next 2Y17.27%
Revenue Next 3Y16.49%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SIBN Yearly Revenue VS EstimatesSIBN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SIBN Yearly EPS VS EstimatesSIBN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SIBN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIBN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SIBN Price Earnings VS Forward Price EarningsSIBN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SIBN Per share dataSIBN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as SIBN's earnings are expected to grow with 14.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.01%
EPS Next 3Y14.39%

More info and screens

0

5. Dividend

5.1 Amount

SIBN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SI-BONE INC

NASDAQ:SIBN (9/26/2025, 8:00:02 PM)

After market: 14.05 0 (0%)

14.05

-0.09 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners91.29%
Inst Owner Change-0.07%
Ins Owners3.01%
Ins Owner Change-1.49%
Market Cap606.12M
Analysts84
Price Target25.5 (81.49%)
Short Float %5.51%
Short Ratio5.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.12%
Min EPS beat(2)25.4%
Max EPS beat(2)34.83%
EPS beat(4)4
Avg EPS beat(4)30.16%
Min EPS beat(4)25.4%
Max EPS beat(4)34.83%
EPS beat(8)8
Avg EPS beat(8)23.87%
EPS beat(12)12
Avg EPS beat(12)23.06%
EPS beat(16)12
Avg EPS beat(16)14.23%
Revenue beat(2)1
Avg Revenue beat(2)0.86%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)2.63%
Revenue beat(4)2
Avg Revenue beat(4)-0.07%
Min Revenue beat(4)-2.34%
Max Revenue beat(4)2.63%
Revenue beat(8)6
Avg Revenue beat(8)1%
Revenue beat(12)9
Avg Revenue beat(12)1.73%
Revenue beat(16)11
Avg Revenue beat(16)1.14%
PT rev (1m)0%
PT rev (3m)1.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.73%
EPS NY rev (1m)0%
EPS NY rev (3m)5.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.27
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB 3.56
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS4.29
BVpS3.95
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.29%
ROE -13.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.45%
FCFM N/A
ROA(3y)-23.71%
ROA(5y)-24.08%
ROE(3y)-35.49%
ROE(5y)-34.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.65%
GM growth 5Y-2.54%
F-Score5
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.61%
Cap/Sales 5.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.38
Quick Ratio 7
Altman-Z 4.67
F-Score5
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)219.68%
Cap/Depr(5y)238.27%
Cap/Sales(3y)6.94%
Cap/Sales(5y)6.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y20%
EPS Next 2Y16.01%
EPS Next 3Y14.39%
EPS Next 5YN/A
Revenue 1Y (TTM)22.93%
Revenue growth 3Y22.84%
Revenue growth 5Y19.96%
Sales Q2Q%21.67%
Revenue Next Year18.3%
Revenue Next 2Y17.27%
Revenue Next 3Y16.49%
Revenue Next 5YN/A
EBIT growth 1Y39.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.65%
EBIT Next 3Y36.68%
EBIT Next 5YN/A
FCF growth 1Y66.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.22%
OCF growth 3YN/A
OCF growth 5YN/A